Core Viewpoint - A new dental clinic, Xingwen Weixiao Dental Clinic Co., Ltd., has been established with a registered capital of 2 million RMB, fully owned by Sichuan Weixiao Dental Hospital Management Co., Ltd. [1] Company Summary - The legal representative of the new clinic is Huang Jiabo [1] - The registered capital of the clinic is 2 million RMB [1] - The clinic is located at No. 52, Jinshan Avenue, Building 1-3-11, Gusu Town, Xingwen County, Yibin City, Sichuan Province [1] - The business scope includes medical services, internet information services, health consulting services (excluding diagnostic services), sales of sanitary products and disposable medical supplies, and marketing planning [1] Shareholder Information - The sole shareholder is Sichuan Weixiao Dental Hospital Management Co., Ltd., holding 100% of the shares [1] Business Operations - The clinic's operations are subject to approval from relevant authorities, and specific business activities will be conducted based on the approval documents or licenses [1] - The business license allows for independent operations except for projects that require approval [1] Registration Details - The company is classified as a limited liability company (non-natural person investment or holding) [1] - The business registration period is from August 21, 2025, with no fixed term [1] - The registration authority is the Xingwen County Market Supervision Administration [1]

本文来自微信公众号：日本通 （ID：ribentong-517japan），作者：九条葱，原文标题：《大量基层医院濒临破产，年轻医生纷纷逃往医美？日本的前车 之鉴或许比想象中更近》，头图来自：AI生成 医院经营的寒冬 提到日本的医疗，人们脑海中往往浮现出一个近乎完美的画面：全民医保覆盖，医院设备先进，医生专业敬业，患者无论贫富都能享受高水平的医疗服 务。的确，日本的国民皆保险制度在全球范围内被誉为典范，合理的医疗费用、便捷的就医途径以及高质量的医疗服务让日本长期以来被视为"医疗天 堂"。然而，这个看似牢不可破的神话正在悄然松动。医院赤字、地方医疗濒临崩溃、年轻医生流向美容外科，这些问题如同暗流，逐渐侵蚀着日本医疗 体系的根基。究竟是什么，让这个曾经引以为傲的体系开始动摇了？ 日本的医院正面临前所未有的经营危机。据日本医院会会长相泽孝夫在2025年6月发布的一段视频中指出，日本约七成的医院处于赤字状态，且赤字规模 逐年扩大。根据日本医院会等六大团体对全国约1700家医院的调查，2024年6月至11月期间，61.2%的医院经营利润为负，医疗业务利润赤字比例更是高 达69%。这组数据令人触目惊心：曾经被视为社会支柱 ...

天眼查显示，近日，广东松鼠通达医院管理有限公司成立，法定代表人为李波，注册资本500万人民 币，由广东松鼠医院投资有限公司全资持股。 经营范围含企业总部管理；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；以自有 资金从事投资活动；医院管理。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动） 序号股东名称持股比例1广东松鼠医院投资有限公司100% 企业名称广东松鼠通达医院管理有限公司法定代表人李波注册资本500万人民币国标行业卫生和社会工 作>卫生>医院地址珠海市横琴港澳大道868号市民服务中心2号楼政务服务中心114室-2509（集中办公 区）企业类型有限责任公司(自然人投资或控股的法人独资)营业期限2025-8-21至无固定期限登记机关横 琴粤澳深度合作区商事服务局 来源：金融界 ...

Core Viewpoint - The company has submitted an application to the China Securities Regulatory Commission (CSRC) to convert 9,286,359 domestic shares into H-shares, pending regulatory approvals [1] Group 1 - The conversion of shares is aimed at allowing the unlisted shares to be traded on the main board of the Stock Exchange of Hong Kong [1] - The company has not yet completed the filing with the CSRC as of the date of the announcement [1]

来源：新浪证券-红岸工作室 三博脑科医院管理集团股份有限公司（以下简称"三博脑科"）近日发布关于持股5%以上股东减持股份 的预披露公告，股东TBP 3Doctors (HK) Limited计划减持公司股份。 减持股东及股份情况 TBP 3Doctors (HK) Limited目前持股数量为31,205,425股，占剔除公司回购专用账户股份数量后总股本 的15.37%，其所持股份全部为无限售条件流通股。股份来源为公司首次公开发行股票并上市前持有的 股份以及该等股份上市后资本公积金转增股本取得的股份。 减持计划详情 减持数量及占比：计划减持6,089,694股，占剔除公司回购专用账户股份数量后总股本的3.00%。其中， 通过集中竞价方式减持不超过2,029,898股（占剔除公司回购专用账户股份数量后总股本的1.00%），通 过大宗交易方式减持不超过4,059,796股（占剔除公司回购专用账户股份数量后总股本的2.00%）。若计 划减持期间内有派息、送股等除权除息事项，减持股份数将相应进行调整。 减持期间：自本公告披露之日起15个交易日后的3个月内。 减持价格：根据减持时的市场价格确定，并根据集中竞价、大宗交易 ...

Group 1 - The core objective of the technical support activity is to enhance the service capabilities and academic influence of medical technology departments through teaching, research, and discipline development [1] - The focus areas of the initiative include the solidification treatment of liver and kidney cysts, microwave ablation of thyroid nodules, and microwave ablation of liver tumors [1] - The "three-dimensional empowerment system" will provide hands-on surgical demonstrations, multidisciplinary perioperative discussions, and the establishment of standardized technical pathways to boost the development of interventional ultrasound in the Zibo region [1] Group 2 - The initiative allows local residents in Zibo and surrounding areas to access top-tier diagnostic and treatment services, aligning with the hospital's commitment to prioritizing public health and distributing quality medical resources [3] - The Zibo Traditional Chinese and Western Medicine Hospital plans to continue deepening technical collaboration and exchanges to enhance the clinical application level of minimally invasive ablation technology [3] - Professor Han Zhiyu will periodically visit the Zibo Traditional Chinese and Western Medicine Hospital for consultations and surgeries, encouraging patients with relevant treatment needs to follow the hospital's public account for updates [3]

Core Points - The hospital acknowledged the existence of a medical dispute regarding a patient's CT imaging error and expressed sincere apologies [1] - The hospital conducted an investigation following complaints from the patient's family about a misdiagnosis due to incorrect imaging [1] - The hospital has communicated and negotiated with the patient and family, and all subsequent tests showed no abnormalities [1] Investigation and Response - The hospital organized relevant departments to investigate the inconsistency in CT examination information [1] - The hospital has committed to further investigations and strict handling of the responsible departments and personnel [1] - The hospital emphasized its commitment to patient-centered care and will enhance medical quality and safety management to prevent similar incidents in the future [1]

胸心外科主任陈晓军于2025年7月前往浙江大学医学院附属邵逸夫医院心外科，跟随国内著名心脏外科专家钱希明教授团队进行 为期半个月的深入学习。学成归来后，陈晓军主任带回国际先进的心脏外科管理理念，并引进前沿技术。 2025/08/13 wisonic 68 圣 [ 结束检查 P7-3T-H(D) TEE Labat SE AP100 MI0.4 TIB0.20 9:42:06 Pat T 37°C TEE T 40.8°C = 术前 180 0 53 10 12 齐鲁晚报.齐鲁壹点王文彬通讯员刘超杜晓萍 wisome LVLJ/VO/ 1. [ـ] 结束检查 P7-3T-H(D) TEE 10:52:33 AP100 MI0.4 TIB0.26 Labat SE Pat T 37°C 3 TEE T 41.7℃ 180 0 术中 5. . S 10 8月13日，滨州市中心医院胸心外科独立完成医院首例改良食道超声(TEE)引导下卵圆孔(PFO)介入封堵术。该手术的成功开展， 标志着医院心脏外科在结构性心脏病微创介入治疗领域取得重大突破，实现了该技术的自主化、精准化应用。 手术患者为一名老年女性，术前检查显示其PF ...

Core Insights - Samsung Medical has 38 hospitals, including 32 rehabilitation hospitals, focusing on building a chain of rehabilitation hospitals with a specialty in critical rehabilitation [1] - The subsidiary Ningbo Mingzhou Hospital is a tertiary Class B general hospital with over 40 departments, including dentistry, ophthalmology, and medical aesthetics [1] - The company, headquartered in Ningbo, is part of the AUX Group and operates in manufacturing, medical services, and financial leasing [1] - In Q1 2025, the company achieved revenue of 3.631 billion yuan, a year-on-year increase of 20.03%, and a net profit attributable to shareholders of 489 million yuan, up 34.33% year-on-year [1]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it indicates a positive trend in the pharmaceutical and biotechnology sector with a weekly increase of 3.08% [3][8]. Core Insights - The pharmaceutical and biotechnology sector outperformed the Wind All A index and the CSI 300 index during the week of August 11 to August 15, with notable gains in medical research outsourcing (7.77%), hospitals (5.59%), and medical consumables (4.47%) [3][8]. - The upcoming launch of the commercial insurance innovative drug directory is expected to activate the domestic high-end payment market for innovative drugs, with 121 drug names passing preliminary review [3][8]. - The World Conference on Lung Cancer (WCLC) will take place from September 6 to 9, showcasing significant research advancements in lung cancer, with domestic research playing an increasingly important role [3][8]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 3.08%, outperforming the Wind All A index (2.95%) and the CSI 300 index (2.37%) [3][8]. - Medical research outsourcing, hospitals, and medical consumables led the sector's gains, while offline pharmacies, blood products, and medical circulation experienced declines [3][8]. - Notable individual stock performances included Sino Medical (69.1%), Innovation Medical (51.5%), and Guangsheng Tang (40.7%) for gains, while *ST Suwu (-16.8%), ST Sansheng (-15.2%), and Nanhua Biological (-14.2%) faced significant losses [3][11]. Industry News and Key Company Announcements - The National Medical Insurance Administration announced the preliminary review of the 2025 National Basic Medical Insurance drug directory and the commercial insurance innovative drug directory [3][13]. - Novo Nordisk received accelerated FDA approval for its therapy Wegovy for treating non-alcoholic steatohepatitis (NASH) [3][13]. - Yunnan Baiyao approved a full acquisition of An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for 660 million RMB to enhance its traditional Chinese medicine business [3][15]. - Insmed's DPP1 inhibitor Brensocatib received FDA approval for treating non-cystic fibrosis bronchiectasis [3][14].